2001
Davey P, Rajan N, Lees M, Aristides M. 2001. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value in Health 4:308–315.
Gliksman MD, Chen J. 2001. Changes in the juvenile crime incidence rate by gender in New South Wales, Australia, 1991–2 to 1996–7. Australian and New Zealand Journal of Criminology 31(3).
Davey P, Graham-Clarke P, Lees M, Thiebaud D, Norris S. 2001. A decision analytic Markov model examining the cost effectiveness of raloxifene, alendronate, hormone replacement therapy and no drug therapy for the prevention of osteoporotic fractures in Australia. In: Bridges J (ed). Economics and Health: 2000. Proceedings of the twenty-second Australian Conference of Health Economists. School of Health Services Management, University of NSW, Sydney. Australian Studies in Health Service Administration No.89:75–88.
Davey P. Commentary. In: Bridges J (ed). Economics and Health: 2000. Proceedings of the twenty-second Australian Conference of Health Economists. School of Health Services Management, University of NSW, Sydney. Australian Studies in Health Service Administration No.89:181–182.
Ekert H, Brewin T, Boey W, Davey P, Tilden D. 2001. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VII or IX. Haemophilia 7:279–285.
Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J. 2001. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica 103:387–392.
Medical Services Advisory Committee (MSAC). 2001. Vertebral axial decompression therapy for chronic back pain. June 2001. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.
McNeill J, Coleman KA. 2001. A meta-analysis of the observed safety and efficacy of ACE inhibitors (ACEIs) and angiotensin II receptor antagonists (AIIRAs) available in Australia on the Pharmaceutical Benefits Schedule (PBS). High Blood Pressure Research Council of Australia, 23rd Annual Scientific Meeting, Melbourne, 13–14 December 2001 (abstract no. 51).
Lees M, Aristides M, Botwood N, McKendrick J, Maniadakis N, Wein W, Stephenson D. 2001. Economic evaluation of Gemzar/cisplatin relative to other new agents for non small cell lung cancer (NSCLC) in the UK. (Value in Health 4(2):86–87 [abstract]).
Stephenson D, Botwood N, McKendrick J, Aristides M, Lees M; Maniadakis N, Wein W. 2001. Economic evaluation of Gemzar in the treatment of pancreatic cancer in the UK. (Value in Health 4(2):86 [abstract]).
McKendrick J, Botwood N, Aristides M, Lees M, Maniadakis N, Wein W, Stephenson D. 2001. Economic evaluation of Gemzar and best supportive care (BSC) relative to best supportive care alone in the treatment of non small cell lung cancer (NSCLC) in the UK. (Value in Health 4(2):86 [abstract]).
Botwood N, McKendrick J, Aristides M, Lees M, Maniadakis N, Wein W, Stephenson D. 2001. Economic evaluation of Gemzar/cisplatin relative to other cisplatin based treatments for non small cell lung cancer (NSCLC) in the UK. (Value in Health 4(2):54–55 [abstract]).
Tilden D, Aristides M, Meddis D, Burns T. 2001. The cost-effectiveness of quetiapine in the treatment of schizophrenic patients partially responsive to previous antipsychotics—an economic analysis of the PRIZE study. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual European Congress. (Value in Health 4:452 [abstract])
Price D, Honeybourne D, Little P, Mayon-White R, Read RC, Wale M, Fitzgerald P, Weston AR. 2001. Recent trends in GP antibiotic prescribing: a potential link to increased community-acquired pneumonia mortality. Thorax 56 (Suppl III):iii26 [abstract].
2000
Shalom B, Langford J, Berry G, Collins D, Lauchlan R, Stewart K, Aristides M, Dobson M. 2000. Economic impact of increased clinical intervention rates in community pharmacy—a randomised trial of the effect of educational and a professional allowance. Pharmacoeconomics 18:459–468.
Davey P, Hristova L, Montgomery B, Grainger D, Aristides M, Chen J. 2000. Schizophrenia Care Assessment Program (SCAP)—epidemiological and health economic assessment of schizophrenia care in Australia. Economics and Health 1999, Proceedings of the 21st Australian Conference of Health Economists, ASHSA No. 87: 151–164.
Chen J, Schulz M, Aristides M, Davey P. 2000. Using conjoint analysis in pharmacoeconomics—statistical considerations and approaches. Economics and Health 1999, Proceedings of the 21st Australian Conference of Health Economists, ASHSA No. 87: 131–148.
Davey PJ, Meyer E. 2000. The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs—implications of the MUCOSA trial. Pharmacoeconomics 17:295–304.
Crowley SJ, Tognarini D, Desmond PV, Lees M. 2000. Cost-effectiveness analysis of lamivudine for treatment of chronic hepatitis B. Pharmacoeconomics 17: 409–427.
1999
Davey P, Hristova L, Montgomery W, Grainger D, Chen J. 1999. Schizophrenia Care Assessment Program (SCAP)—epidemiological health economic assessment of schizophrenia care in Australia. Australian Health Economics Society, Canberra.
de Castella A, Kulkarni K, Montgomery W, Rolfe T, Jafari A Corteling N, Davey P, Hristova L. The Schizophrenia Care Assessment Program (SCAP): a preliminary analysis of primary data 1999. World Congress on Schizophrenia, Santa Fe.
Gibson J, Hristova L, Davey P, Montgomery W, Kulkani J, deCastella A. 1999. A Schizophrenia Care Assessment Program: initial findings on health care resource utilisation in Australia. International Society of Pharmacoeconomics and Outcomes Research, US.
Hristova L, Adams A, Corteling N, Davey P, Montgomery W, Kulkarni J, Rolfe T. 1999. Schizophrenia Care and Assessment Program—health outcomes at baseline. International Health Outcomes Conference, Canberra.
Rolfe T, Kulkarni J, Fitzgerald P, Montgomery W, Jafari A, Corteling N, Williams C, deCastella A, Davey P, Hopkins S, Hristova L, Chen J, Thomas T. 1999. Cannabis use, symptom profile and quality of life in clients enrolled in the Schizophrenia Care and Assessment Program (SCAP). World Congress on Schizophrenia, Santa Fe.
1998
Aristides M, Gliksman M, Rajan N, Davey P. 1998. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 79:12–17.
Aristides M, Gliksman M. 1998. Murmurs from the heart (or why the stethoscope is not an economic tool). Heart 79:10–11.
Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. 1998. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 13:347–358.
Drummond M, Aristides M. 1998. The Australian cost-effectiveness guidelines: an update. In: Towse A(ed). Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? Office of Health Economics, London.
Davey P. 1998. Health Economics: an Assessment of Oral Antibiotic Therapy. Round Table Series 55. The Royal Society of Medicine Press, London, pp 77–81.
Davey P, Schulz M, Gliksman M, Dobson M, Aristides M, Stephens NG. 1998 Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial) American Journal of Cardiology 82:414–417.
Aristides M, Chen C, Schulz M, Williamson E, Clarke S, Davey P, Grant K. 1998. Economic evaluation of raltitrexed (Tomudex™) in advanced colorectal cancer. Proceedings of the Clinical Oncology Society of Australia.
Kulkarni J, Montgomery W, Jafari A, Corteling N, Davey P, Hopkins S, Thomas A. 1998. The Schizophrenia Care and Assessment Program (SCAP): a preliminary analysis. 5th Australasian Schizophrenia Conference, Hobart, Tasmania.
Kulkarni J, Montgomery W, Rolfe T, deCastella A, Jafari A, Corteling N, Davey P, Hristova L. 1998. Outcomes measurement in schizophrenia: initial experience with the Schizophrenia Care and Assessment Program (SCAP). 5th Australasian Schizophrenia Conference, Hobart, Tasmania.
Rolfe T, Kulkarni J, Fitzgerald P, Montgomery W, Jafari A, Corteling N, deCastella A, Davey P, Hopkins S, Thomas A. 1998. Cannabis use, symptom profile and quality of life in clients enrolled in the Schizophrenia Care and Assessment Program (SCAP). 5th Australasian Schizophrenia Conference, Hobart, Tasmania.